Penn Medicine Co-Investment Program

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

CareAlign is a developer of a real-time data system that enhances the management and coordination of clinical care for clinicians. The company offers an intuitive, patient-centric task management tool that allows healthcare professionals to assign tasks, set deadlines, and categorize them based on urgency. By aggregating data from multiple sources, CareAlign provides a comprehensive and clinically intuitive display of patients' clinical status, facilitating better understanding and decision-making in patient care. This system aims to streamline workflows and improve communication among clinicians, ultimately enhancing the quality of care delivered to patients.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Linnaeus Therapeutics is a development-stage biotechnology company focused on identifying and advancing small molecule therapeutics that modulate cellular differentiation to treat cancer and pigmentation disorders. Based in Haddonfield, New Jersey, the company originated as a Penn Center for Innovation UPstart venture founded on discoveries from the Ridky laboratory at the University of Pennsylvania and was established around 2015–2016. Its molecular agents are designed to influence melanin production in skin cells, enabling treatment of cancers and pigmentation disorders driven by oncogenic mutations.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology, chimeric autoantibody receptor (CAAR) T cells, selectively targets and eliminates disease-causing B cells while sparing healthy ones. Cabaletta's lead product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris.

Linnaeus Therapeutics is a development-stage biotechnology company focused on identifying and advancing small molecule therapeutics that modulate cellular differentiation to treat cancer and pigmentation disorders. Based in Haddonfield, New Jersey, the company originated as a Penn Center for Innovation UPstart venture founded on discoveries from the Ridky laboratory at the University of Pennsylvania and was established around 2015–2016. Its molecular agents are designed to influence melanin production in skin cells, enabling treatment of cancers and pigmentation disorders driven by oncogenic mutations.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.